Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis

Sombat Treeprasertsuk, Marina G. Silveira, Janice L. Petz, Keith D. Lindor

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

We aimed to describe the effects of parenteral bisphosphonates on bone mineral density (BMD) changes in primary biliary cirrhosis (PBC) patients with osteoporosis. Seventeen PBC patients with osteoporosis diagnosed between 1996 and 2005 were enrolled retrospectively. All patients received one of the following parenteral bisphosphonates: zoledronic acid, pamidronate disodium, or ibandronate sodium. The median (interquartile range) age of patients at osteoporosis diagnosis was 62.2 (56.4-67.9) and 94% were women. After treatment, percent change of lumbar spine bone mineral density (LS-BMD) and proximal femur BMD (PF-BMD) of patients with PBC was 2.9% and 0.4%, respectively. Eight patients (47%) showed a greater LS-BMD and/or PF-BMD with percent change of LS-BMD and PF-BMD of 8.7% and 0.8%, respectively. No serious adverse events were found. In PBC patients with osteoporosis, parenteral bisphosphonates can stabilize BMD for 47% of patients. More prospective studies are needed to evaluate the efficacy of specific parenteral bisphosphonates in patients with PBC and osteoporosis.

Original languageEnglish (US)
Pages (from-to)375-381
Number of pages7
JournalAmerican Journal of Therapeutics
Volume18
Issue number5
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

    Fingerprint

Keywords

  • bone disease
  • parenteral bisphosphonates
  • primary biliary cirrhosis
  • treatment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this